These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 39066247)

  • 21. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium.
    Khawaja F; Spallone A; Kotton CN; Chemaly RF
    Clin Microbiol Infect; 2023 Jan; 29(1):44-50. PubMed ID: 35843567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
    Foolad F; Aitken SL; Chemaly RF
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
    Hecke SV; Calcoen B; Lagrou K; Maertens J
    Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.
    Ljungman P; Chemaly RF; Khawaya F; Alain S; Avery R; Badshah C; Boeckh M; Fournier M; Hodowanec A; Komatsu T; Limaye AP; Manuel O; Natori Y; Navarro D; Pikis A; Razonable RR; Westman G; Miller V; Griffiths PD; Kotton CN;
    Clin Infect Dis; 2024 Sep; 79(3):787-794. PubMed ID: 39041385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence.
    Haidar G; Boeckh M; Singh N
    J Infect Dis; 2020 Mar; 221(Suppl 1):S23-S31. PubMed ID: 32134486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective.
    Schultz BG; Kotton CN; Jutlla G; Ressa R; de Lacey T; Chowdhury E; Bo T; Fenu E; Gelone DK; Poirrier JE; Amorosi SL
    J Med Virol; 2024 Apr; 96(4):e29609. PubMed ID: 38647051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients.
    Royston L; Royston E; Masouridi-Levrat S; Chalandon Y; Van Delden C; Neofytos D
    Immun Inflamm Dis; 2021 Sep; 9(3):771-776. PubMed ID: 33949798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.
    Johnsrud JJ; Nguyen IT; Domingo W; Narasimhan B; Efron B; Brown JW
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1963-1970. PubMed ID: 32653623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
    Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM; Villano S
    Clin Infect Dis; 2019 Apr; 68(8):1255-1264. PubMed ID: 30329038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus.
    Germi R; Mariette C; Alain S; Lupo J; Thiebaut A; Brion JP; Epaulard O; Saint Raymond C; Malvezzi P; Morand P
    Antiviral Res; 2014 Jan; 101():57-61. PubMed ID: 24184983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.
    Santos Bravo M; Tilloy V; Plault N; Palomino SS; Mosquera MM; Navarro Gabriel M; Fernández Avilés F; Suárez Lledó M; Rovira M; Moreno A; Linares L; Bodro M; Hantz S; Alain S; Marcos MÁ
    Microbiol Spectr; 2022 Apr; 10(2):e0019122. PubMed ID: 35343771
    [No Abstract]   [Full Text] [Related]  

  • 35. Update on cytomegalovirus in transplant recipients: new agents, prophylaxis, and cell-mediated immunity.
    Manuel O; Avery RK
    Curr Opin Infect Dis; 2021 Aug; 34(4):307-313. PubMed ID: 34074879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
    Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
    Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.
    Santos Bravo M; Plault N; Sánchez Palomino S; Mosquera Gutierrez MM; Fernández Avilés F; Suarez Lledo M; Sabé Fernández N; Rovira M; Alain S; Marcos Maeso MÁ
    J Infect Dis; 2021 Sep; 224(6):1024-1028. PubMed ID: 33475730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation.
    Meesing A; Razonable RR
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):773-788. PubMed ID: 30009675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients.
    Veit T; Munker D; Kauke T; Zoller M; Michel S; Ceelen F; Schiopu S; Barton J; Arnold P; Milger K; Behr J; Kneidinger N
    Transplantation; 2020 Feb; 104(2):410-414. PubMed ID: 31385924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.